Patrick Chi-Chung Ma, MD, MSc - Penn State Cancer Institute
Researcher Profile
Patrick Chi-Chung Ma, MD, MSc
Professor, Department of Medicine
Interim Chief, Division of Hematology and Oncology
Professor, Department of Molecular and Precision Medicine
Interim Chief, Division of Hematology and Oncology
Professor, Department of Molecular and Precision Medicine
Scientific Program:Next-Generation Therapies
Clinical Trials
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without Radiation Therapy for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
A Phase I/II Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C mutation (KRYSTAL-1) (MRT849-001)
NRG HN009- Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
NRG-LU008: Phase III Prospective Randomized Trial Of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed By Concurrent Mediastinal Chemoradiation For Locally Advanced Non-Small Cell Lung Cancer
A randomized phase II trial of adjuvant Pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153
NRG-LU007 Randomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial
Recent Publications
2024
Pecci, F, Nakazawa, S, Ricciuti, B, Harada, G, Lee, JK, Alessi, JV, Barrichello, A, Vaz, VR, Lamberti, G, Di Federico, A, Gandhi, MM, Gazgalis, D, Feng, WW, Jiang, J, Baldacci, S, Locquet, MA, Gottlieb, FH, Chen, MF, Lee, E, Haradon, D, Smokovich, A, Voligny, E, Nguyen, T, Goel, VK, Zimmerman, Z, Atwal, S, Wang, X, Bahcall, M, Heist, RS, Iqbal, S, Gandhi, N, Elliott, A, Vanderwalde, AM, Ma, PC, Halmos, B, Liu, SV, Che, J, Schrock, AB, Drilon, A, Jänne, PA & Awad, MM 2024, 'Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors', Cancer Discovery, vol. 14, no. 8, pp. 1440-1456. https://doi.org/10.1158/2159-8290.CD-23-1217
Luo, J, Florez, N, Donnelly, A, Lou, Y, Lu, K, Ma, PC, Spira, AI, Ryan, D & Husain, H 2024, 'Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With KRASG12C-Mutated Non–Small Cell Lung Cancer: A Case Series and Literature Review', JCO Precision Oncology, vol. 8, e2300644. https://doi.org/10.1200/PO.23.00644
Bodor, JN, Xiu, J, Ernani, V, Kaur, S, Mamdani, H, Ou, SHI, Ma, PC, Borghaei, H, Clapper, ML, VanderWalde, A & Treat, J 2024, 'Brief Report: The Immune Profiles of the Molecular Subtypes of EGFR-Mutant Lung Adenocarcinomas in a Large Real-World Cohort', Clinical Lung Cancer, vol. 25, no. 7, pp. e312-e315.e1. https://doi.org/10.1016/j.cllc.2024.04.016
Morgenstern-Kaplan, D, Kareff, SA, Trabolsi, A, Rodriguez, E, Krause, H, Ribeiro, JR, Tan, H, Antonarakis, ES, Lou, E, Nagasaka, M, Algaze, S, Lenz, HJ, Liu, SV, Halmos, B, Hoon, DSB, Seeber, A, Ma, PC, El-Deiry, WS, Vanderwalde, AM & Lopes, G 2024, 'Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors', Oncologist, vol. 29, no. 11, pp. e1480-e1491. https://doi.org/10.1093/oncolo/oyae168
Naqash, AR, Floudas, CS, Aber, E, Maoz, A, Nassar, AH, Adib, E, Choucair, K, Xiu, J, Baca, Y, Ricciuti, B, Alessi, JV, Awad, MM, Kim, C, Judd, J, Raez, LE, Lopes, G, Nieva, JJ, Borghaei, H, Takebe, N, Ma, PC, Halmos, B, Kwiatkowski, DJ, Liu, SV & Mamdani, H 2024, 'Influence of TP53 Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in STK11-Mutant Non–Small-Cell Lung Cancer', JCO Precision Oncology, vol. 8, e2300371. https://doi.org/10.1200/PO.23.00371
Marks, JA, Gandhi, N, Halmos, B, Marmarelis, ME, Yeon Kim, S, Bazhenova, L, Ramalingam, SS, Xiu, J, Walker, P, Oberley, MJ, Ma, PC & Liu, SV 2024, 'Molecular profiling METex14+ non-small cell lung cancer (NSCLC): Impact of histology', Lung Cancer, vol. 196, 107935. https://doi.org/10.1016/j.lungcan.2024.107935
Hsiehchen, D, Elliott, A, Xiu, J, Seeber, A, El-Deiry, W, Antonarakis, ES, Graff, SL, Hall, MJ, Borghaei, H, Hoon, DSB, Liu, SV, Ma, PC, McKay, RR, Wise-Draper, T, Marshall, J, Sledge, GW, Spetzler, D & Zhu, H 2024, 'Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activation', Cancer Cell, vol. 42, no. 12, pp. 1985-1987. https://doi.org/10.1016/j.ccell.2024.10.017
Lim, ZF, Wu, X, Zhu, L, Albandar, H, Hafez, M, Zhao, C, Almubarak, M, Smolkin, M, Zheng, H, Wen, S & Ma, PC 2024, 'Quantitative peripheral live single T-cell dynamic polyfunctionality profiling predicts lung cancer checkpoint immunotherapy treatment response and clinical outcomes', Translational Lung Cancer Research, vol. 13, no. 12, pp. 3323-3343. https://doi.org/10.21037/tlcr-24-260
Dmukauskas, M, Cioffi, G, Waite, KA, Mammoser, AG, Sloan, AE, Ma, PC & Barnholtz-Sloan, JS 2024, 'Sex Difference in Disease-Related Adverse Events Post-Diagnosis of Lung Cancer Brain Metastases in Medicare Individuals ≥ 66 Years of Age', Cancers, vol. 16, no. 17, 2986. https://doi.org/10.3390/cancers16172986
Muquith, M, Espinoza, M, Elliott, A, Xiu, J, Seeber, A, El-Deiry, W, Antonarakis, ES, Graff, SL, Hall, MJ, Borghaei, H, Hoon, DSB, Liu, SV, Ma, PC, McKay, RR, Wise-Draper, T, Marshall, J, Sledge, GW, Spetzler, D, Zhu, H & Hsiehchen, D 2024, 'Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers', Nature Cancer, vol. 5, no. 7, pp. 1121-1129. https://doi.org/10.1038/s43018-024-00752-x
Watson, AS, Krause, HB, Elliott, A, Farrell, A, Liu, SV, Ma, PC, VanderWalde, A, Sledge, GW, Spetzler, D, Schenk, EL & Camidge, DR 2024, 'Use of Oncogene Overlap by Tissue-Based Next-Generation Sequencing to Explore the Mutational Landscape and Survival Impact of HER2, KRAS and MET Copy-Number Gain in Nonsmall Cell Lung Cancer', Clinical Lung Cancer, vol. 25, no. 8, pp. 712-722.e1. https://doi.org/10.1016/j.cllc.2024.09.001
2023
Guo, T, Zhao, S, Wang, P, Xue, X, Zhang, Y, Yang, M, Li, N, Li, Z, Xu, L, Jiang, L, Zhao, L, Ma, PC, Rosell, R, Li, J & Gu, C 2023, 'Erratum: YB-1 regulates tumor growth by promoting MACC1/c-Met pathway in human lung adenocarcinoma (Oncotarget (2017) 8 (48110-48125) DOI: 10.18632/oncotarget.18262)', Oncotarget, vol. 14, no. 1, pp. 280. https://doi.org/10.18632/oncotarget.28393
2022
Kim, SY, Yin, J, Bohlman, S, Walker, P, Dacic, S, Kim, C, Khan, H, Liu, SV, Ma, PC, Nagasaka, M, Reckamp, KL, Abraham, J, Uprety, D, Wang, F, Xiu, J, Zhang, J, Cheng, H & Halmos, B 2022, 'Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing', JTO Clinical and Research Reports, vol. 3, no. 9, 100381. https://doi.org/10.1016/j.jtocrr.2022.100381
Esposito, R, Polidori, T, Meise, DF, Pulido-Quetglas, C, Chouvardas, P, Forster, S, Schaerer, P, Kobel, A, Schlatter, J, Kerkhof, E, Roemmele, M, Rice, ES, Zhu, L, Lanzós, A, Guillen-Ramirez, HA, Basile, G, Carrozzo, I, Vancura, A, Ullrich, S, Andrades, A, Harvey, D, Medina, PP, Ma, PC, Haefliger, S, Wang, X, Martinez, I, Ochsenbein, AF, Riether, C & Johnson, R 2022, 'Multi-hallmark long noncoding RNA maps reveal non-small cell lung cancer vulnerabilities', Cell Genomics, vol. 2, no. 9, 100171. https://doi.org/10.1016/j.xgen.2022.100171
Shen, C, Holguin, RAP, Schaefer, E, Zhou, S, Belani, CP, Ma, PC & Reed, MF 2022, 'Utilization and costs of epidermal growth factor receptor mutation testing and targeted therapy in Medicare patients with metastatic lung adenocarcinoma', BMC health services research, vol. 22, no. 1, 470. https://doi.org/10.1186/s12913-022-07857-y
2021
Mattes, MD, Eubank, TD, Almubarak, M, Wen, S, Marano, GD, Jacobson, GM & Ma, PC 2021, 'A Prospective Trial Evaluating the Safety and Systemic Response From the Concurrent Use of Radiation Therapy with Checkpoint Inhibitor Immunotherapy in Metastatic Non–Small Cell Lung Cancer', Clinical Lung Cancer, vol. 22, no. 4, pp. 268-273. https://doi.org/10.1016/j.cllc.2021.01.012
Ma, PC 2021, 'ADAURA: The role of adjuvant EGFR TKI and future consideration (Pro)', Precision Cancer Medicine, vol. 4, no. March, 6. https://doi.org/10.21037/pcm-2020-mnsclc-10
Khan, SA, Sun, Z, Dahlberg, S, Malhotra, J, Keresztes, R, Ikpeazu, C, Ma, P, Ramalingam, SS & Pillai, R 2021, 'Efficacy and Safety of Glembatumumab Vedotin in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Lung (PrECOG 0504)', JTO Clinical and Research Reports, vol. 2, no. 5, 100166. https://doi.org/10.1016/j.jtocrr.2021.100166
He, Y, Chen, L, Zhao, L, Dang, S, Liu, G, Sasada, S, Ma, PC, Zandwijk, NV, Rosell, R, Popper, HH, Wang, H, Jiang, M, Guo, H, Liu, X, Chen, S, Zhang, X, Xu, M, Zhu, B, Liu, M & Zhou, C 2021, 'Genomic and transcriptional alterations in first-line chemotherapy exert a potentially unfavorable influence on subsequent immunotherapy in NSCLC', Theranostics, vol. 11, no. 14, pp. 7092-7109. https://doi.org/10.7150/thno.58039
Albandar, HJ, Fuqua, J, Albandar, JM, Safi, S, Merrill, SA & Ma, PC 2021, 'Immune-related adverse events (Irae) in cancer immune checkpoint inhibitors (ici) and survival outcomes correlation: To rechallenge or not?', Cancers, vol. 13, no. 5, 989, pp. 1-15. https://doi.org/10.3390/cancers13050989
Nagasaka, M, Asad, MFB, Al Hallak, MN, Uddin, MH, Sukari, A, Baca, Y, Xiu, J, Magee, D, Mamdani, H, Uprety, D, Kim, C, Xia, B, Liu, SV, Nieva, JJ, Lopes, G, Bepler, G, Borghaei, H, Demeure, MJ, Raez, LE, Ma, PC, Puri, S, Korn, WM & Azmi, AS 2021, 'Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC)', Lung Cancer, vol. 160, pp. 92-98. https://doi.org/10.1016/j.lungcan.2021.08.010
Lee, M, Jain, P, Wang, F, Ma, PC, Borczuk, A & Halmos, B 2021, 'MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies', Expert Opinion on Therapeutic Targets, vol. 25, no. 4, pp. 249-268. https://doi.org/10.1080/14728222.2021.1925648